Fate Therapeutics, Inc.
NASDAQ:FATEBiotechnology
-$0.00 today
- Market cap
- $122.39M
- Beta
- 2.52
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.08
Volume 1.87M
Average 2.92M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Fate Therapeutics, Inc.
NASDAQ:FATE
Intrinsic Alpha fair value
Locked
Current Price
$1.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | -59.0% | +73.8% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Recent growth has been strongest in Revenue at -59.0% over three years. Forward estimates point to Revenue at +73.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Vor Biopharma Inc. NASDAQ:VOR | $1.05B | $19.42 | Not rated | -0.0 | +128.01% |
Alector, Inc. NASDAQ:ALEC | $378.15M | $2.54 | Not rated | -1.4 | +110.66% |
PepGen Inc. NASDAQ:PEPG | $301.98M | $4.36 | Not rated | -1.6 | -30.74% |
Prelude Therapeutics Incorporated NASDAQ:PRLD | $275.32M | $3.45 | Not rated | -4.5 | +97.60% |
Molecular Partners AG NASDAQ:MOLN | $112.71M | $2.94 | Not rated | -2.0 | -36.40% |
Inovio Pharmaceuticals, Inc. NASDAQ:INO | $98.80M | $1.43 | Not rated | -8.9 | -5.06% |
Nkarta, Inc. NASDAQ:NKTX | $85.23M | $1.19 | Not rated | -2.0 | -35.75% |
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP | $69.86M | $3.39 | Not rated | -1.3 | -76.78% |
Acumen Pharmaceuticals, Inc. NASDAQ:ABOS | $15.48M | $0.21 | Not rated | -1.3 | +47.74% |
Continue the stock analysis
Jump to another research area for this company.